Clinical Research Directory
Browse clinical research sites, groups, and studies.
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Sponsor: Henan Cancer Hospital
Summary
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104 with chemotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA NSCLC.
Official title: A Single-Arm, Phase II Study of AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2022-07-26
Completion Date
2027-12-31
Last Updated
2024-02-21
Healthy Volunteers
No
Conditions
Interventions
AK104
10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Albumin-Bound Paclitaxel
260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
Carboplatin
AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
Locations (1)
Henan Cancer Hospital
Zhengzhou, Henan, China